Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 105

1.

Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation.

Liu P, Wysocki J, Souma T, Ye M, Ramirez V, Zhou B, Wilsbacher LD, Quaggin SE, Batlle D, Jin J.

Kidney Int. 2018 Jul;94(1):114-125. doi: 10.1016/j.kint.2018.01.029. Epub 2018 Apr 22.

PMID:
29691064
2.

The Urine Anion Gap in Context.

Batlle D, Ba Aqeel SH, Marquez A.

Clin J Am Soc Nephrol. 2018 Feb 7;13(2):195-197. doi: 10.2215/CJN.13791217. Epub 2018 Jan 8. No abstract available.

PMID:
29311217
3.

Angiotensinogen as a biomarker of acute kidney injury.

Ba Aqeel SH, Sanchez A, Batlle D.

Clin Kidney J. 2017 Dec;10(6):759-768. doi: 10.1093/ckj/sfx087. Epub 2017 Jul 28. Review.

4.

Metabolic Acidosis or Respiratory Alkalosis? Evaluation of a Low Plasma Bicarbonate Using the Urine Anion Gap.

Batlle D, Chin-Theodorou J, Tucker BM.

Am J Kidney Dis. 2017 Sep;70(3):440-444. doi: 10.1053/j.ajkd.2017.04.017. Epub 2017 Jun 7.

PMID:
28599903
5.

Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease.

Wysocki J, Goodling A, Burgaya M, Whitlock K, Ruzinski J, Batlle D, Afkarian M.

Am J Physiol Renal Physiol. 2017 Aug 1;313(2):F487-F494. doi: 10.1152/ajprenal.00074.2017. Epub 2017 May 3.

6.

A Fluorometric Method of Measuring Carboxypeptidase Activities for Angiotensin II and Apelin-13.

Liu P, Wysocki J, Serfozo P, Ye M, Souma T, Batlle D, Jin J.

Sci Rep. 2017 Apr 5;7:45473. doi: 10.1038/srep45473.

7.

Hypertension and Its Complications in a Young Man With Autoimmune Disease.

Miller-Hodges E, Dominiczak AF, Jennings GL, Oparil S, Batlle DC, Elijovich F, Basile JN, Laffer CL, Oliveras A, Dhaun N.

Hypertension. 2017 Apr;69(4):536-544. doi: 10.1161/HYPERTENSIONAHA.117.09036. Epub 2017 Feb 27. No abstract available.

PMID:
28242716
8.

Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II.

Maier C, Schadock I, Haber PK, Wysocki J, Ye M, Kanwar Y, Flask CA, Yu X, Hoit BD, Adams GN, Schmaier AH, Bader M, Batlle D.

J Mol Med (Berl). 2017 May;95(5):473-486. doi: 10.1007/s00109-017-1513-9. Epub 2017 Feb 3.

PMID:
28160049
9.

Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy.

Wysocki J, Ye M, Khattab AM, Fogo A, Martin A, David NV, Kanwar Y, Osborn M, Batlle D.

Kidney Int. 2017 Jun;91(6):1336-1346. doi: 10.1016/j.kint.2016.09.032. Epub 2016 Dec 4.

10.

Urinary Angiotensinogen: A Promising Biomarker of AKI Progression in Acute Decompensated Heart Failure: What Does It Mean?

Wysocki J, Batlle D.

Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1515-7. doi: 10.2215/CJN.07780716. Epub 2016 Aug 18. No abstract available.

11.

The Colon as the Potassium Target: Entering the Colonic Age of Hyperkalemia Treatment?

Batlle D, Boobés K, Manjee KG.

EBioMedicine. 2015 Oct 29;2(11):1562-3. doi: 10.1016/j.ebiom.2015.10.027. eCollection 2015 Nov. No abstract available.

12.

Snapshot Hemodynamics and Clinical Outcomes in Hypertension: Precision in the Measurements Is Key.

Pandit JA, Batlle D.

Hypertension. 2016 Feb;67(2):270-1. doi: 10.1161/HYPERTENSIONAHA.115.06818. Epub 2015 Dec 22. Review. No abstract available.

PMID:
26693819
13.

Angiotensins and the heart: is angiotensin-(1-7) cardioprotective?

Wysocki J, Wilsbacher L, Batlle D.

Hypertension. 2015 Aug;66(2):260-2. doi: 10.1161/HYPERTENSIONAHA.115.05093. Epub 2015 Jun 15. No abstract available.

14.

Plasma and Kidney Angiotensin Peptides: Importance of the Aminopeptidase A/Angiotensin III Axis.

Wysocki J, Ye M, Batlle D.

Am J Hypertens. 2015 Dec;28(12):1418-26. doi: 10.1093/ajh/hpv054. Epub 2015 May 11.

15.

Cross-Disciplinary Biomarkers Research: Lessons Learned by the CKD Biomarkers Consortium.

Hsu CY, Ballard S, Batlle D, Bonventre JV, Böttinger EP, Feldman HI, Klein JB, Coresh J, Eckfeldt JH, Inker LA, Kimmel PL, Kusek JW, Liu KD, Mauer M, Mifflin TE, Molitch ME, Nelsestuen GL, Rebholz CM, Rovin BH, Sabbisetti VS, Van Eyk JE, Vasan RS, Waikar SS, Whitehead KM, Nelson RG; CKD Biomarkers Consortium.

Clin J Am Soc Nephrol. 2015 May 7;10(5):894-902. doi: 10.2215/CJN.11541114. Epub 2015 Mar 4. Review.

16.

ACE2 deficiency increases NADPH-mediated oxidative stress in the kidney.

Wysocki J, Ortiz-Melo DI, Mattocks NK, Xu K, Prescott J, Evora K, Ye M, Sparks MA, Haque SK, Batlle D, Gurley SB.

Physiol Rep. 2014 Mar 24;2(3):e00264. doi: 10.1002/phy2.264. Print 2014.

17.

Endothelin receptor-A antagonist attenuates retinal vascular and neuroretinal pathology in diabetic mice.

Chou JC, Rollins SD, Ye M, Batlle D, Fawzi AA.

Invest Ophthalmol Vis Sci. 2014 Apr 17;55(4):2516-25. doi: 10.1167/iovs.13-13676.

18.

Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro.

Haber PK, Ye M, Wysocki J, Maier C, Haque SK, Batlle D.

Hypertension. 2014 Apr;63(4):774-82. doi: 10.1161/HYPERTENSIONAHA.113.02856. Epub 2014 Jan 20.

19.

Effect of insulin on ACE2 activity and kidney function in the non-obese diabetic mouse.

Riera M, Márquez E, Clotet S, Gimeno J, Roca-Ho H, Lloreta J, Juanpere N, Batlle D, Pascual J, Soler MJ.

PLoS One. 2014 Jan 6;9(1):e84683. doi: 10.1371/journal.pone.0084683. eCollection 2014. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/2a7b69d2-a049-448e-b584-51e4c1e8a50d.

20.

Reduced plasma ACE2 activity in dialysis patients: another piece in the conundrum of factors involved in hypertension and cardiovascular morbidity?

Wysocki J, Batlle D.

Nephrol Dial Transplant. 2013 Sep;28(9):2200-2. doi: 10.1093/ndt/gft240. Epub 2013 Jun 19. No abstract available.

Supplemental Content

Loading ...
Support Center